What changed today in Metabolic: 4 trial updates, 1 new study
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records6 sources1 min read
Lean mass & body composition
How weight-loss therapies affect lean mass, muscle and body composition, and the strategies studied to preserve muscle during weight reduction.
Building
- Editorial attention
- Building
- Tracked this week
- 8
- Sources this week
- 5
- Last activity
- 3 days ago
Signal strength reflects editorial attention across tracked sources — not medical certainty or strength of evidence.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
Lean mass & body composition at a glance
- About this topic
- How weight-loss therapies affect lean mass, muscle and body composition, and the strategies studied to preserve muscle during weight reduction.
- Current status
- No editor-reviewed status summary yet. The official records below update automatically.
- Last updated
- Primary sources
- Latest official record: Weight, Fat Mass, and Lean Mass Changes After Bariatric Surgery and GLP-1-Based Therapy: A Systematic Review and Meta-Analysis (opens the source in a new tab) (Obesity surgery, Nov 12, 2026)
- Key facts from tracked records
- 14 NPHLA briefings on this topic
What’s the latest on Lean mass & body composition?
14 totalWhat changed today in Metabolic: 13 trial updates, 2 new studies
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records13 sources1 min read
What changed today in Metabolic: 5 trial updates, 1 new study
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records9 sources1 min read
What changed today in Metabolic: 5 trial updates, 3 new studies
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records11 sources1 min read
What changed today in Metabolic: 4 new studies, 2 trial updates
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records6 sources1 min read
What changed today in Metabolic: 4 trial updates, 3 new studies
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records10 sources1 min read
What changed today in Metabolic: 1 trial update
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records1 source1 min read
What changed today in Metabolic: 8 trial updates
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records9 sources1 min read
What do the official records show?
Primary sources and peer-reviewed research- Weight, Fat Mass, and Lean Mass Changes After Bariatric Surgery and GLP-1-Based Therapy: A Systematic Review and Meta-Analysis (opens the source in a new tab)
- New trial registered: Effects of a Gut-Active Peptide That Stimulates GLP-1 Release on Appetite and Satiety in Healthy Adults With Overweight (opens the source in a new tab)
Not applicable, Lembas. Conditions: Appetite and Hunger, Suppression; Satiety and Appetite; Weight Change; Gastrointestinal Symptoms; Body Composition. Interventions: Lembas Edge™; Placebo. Investigational: trial-stage therapies are not approved for the use studied.
- Will sarcopenia preventative pharmacology ensure the long-term success of GLP-1-derived therapies? (opens the source in a new tab)
- New trial registered: Changes in Body Composition and Muscle Composition After GLP-1 Receptor Agonist Therapy in Patients With Obesity (opens the source in a new tab)
Ulsan University Hospital. Conditions: Obesity & Overweight. Interventions: . Investigational: trial-stage therapies are not approved for the use studied.
- Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial (opens the source in a new tab)
- New trial registered: IMPACT (The Impact of Incretins on Fat-free Mass, Muscle Strength and Functional Capacity) (opens the source in a new tab)
Radboud University Medical Center. Conditions: Obesity & Overweight. Interventions: . Investigational: trial-stage therapies are not approved for the use studied.
- Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial (opens the source in a new tab)
- New trial registered: COMPACT (Exercise and Protein to Reduce Muscle Loss During GLP-1-Based Treatment in Type 2 Diabetes) (opens the source in a new tab)
Not applicable, German Diabetes Center. Conditions: Type 2 Diabetes (T2DM); Obesity & Overweight; Sarcopenia. Interventions: Supervised exercise training; protein supplement; Standardized lifestyle counseling. Investigational: trial-stage therapies are not approved for the use…